Trial Profile

Phase II Clinical Study of Utidelone Capsule (UTD2) in Patients With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 10 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Depoxythilone (Primary)
Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Focus Adverse reactions
Sponsors BioStar Pharmaceuticals

Most Recent Events

15 Sep 2025 Status changed to recruiting.
15 Sep 2025 According to Beijing Biostar Pharmaceuticals media release, the first patients have been dosed for the phase II/III for UTD2 treatment for platinum-resistant advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer on 12 Sep 2025 .
08 Jul 2025 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com